These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 19451225)

  • 1. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
    James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
    Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
    James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
    Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.
    López-Lago MA; Okada T; Murillo MM; Socci N; Giancotti FG
    Mol Cell Biol; 2009 Aug; 29(15):4235-49. PubMed ID: 19451229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
    Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
    Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
    Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
    Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
    Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
    Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
    James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
    Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
    Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
    Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma.
    Maze EA; Agit B; Reeves S; Hilton DA; Parkinson DB; Laraba L; Ercolano E; Kurian KM; Hanemann CO; Belshaw RD; Ammoun S
    Cancer Res; 2022 Jan; 82(2):235-247. PubMed ID: 34853069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
    Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
    Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
    Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.
    Acosta-Jaquez HA; Keller JA; Foster KG; Ekim B; Soliman GA; Feener EP; Ballif BA; Fingar DC
    Mol Cell Biol; 2009 Aug; 29(15):4308-24. PubMed ID: 19487463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
    Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
    Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
    Sato T; Sekido Y
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
    Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
    EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
    Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
    Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
    Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
    Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
    Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
    Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.